DBV Technologies (DBVT) Total Non-Current Liabilities (2014 - 2026)
DBV Technologies (DBVT) reported Total Non-Current Liabilities of $6.7 million for Q1 2026, down 8.28% year-over-year from $7.3 million in Q1 2025, and down 2.9% on a QoQ basis from $6.9 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Total Non-Current Liabilities data on file, last reported at $6.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 8.28% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 8.28% YoY) and the FY2025 annual result came in at $6.9 million, down 3.29% from the prior year.
- Total Non-Current Liabilities eased to $6.7 million in Q1 2026 per DBVT's latest filing, from $6.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $22.5 million in Q4 2022 and bottomed at $5.5 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $7.8 million (2025), against an average of $10.5 million.
- Peak annual rise in Total Non-Current Liabilities reached 121.92% in 2023, while the deepest fall reached 75.78% in 2023.
- Tracing DBVT's Total Non-Current Liabilities over 5 years: stood at $22.5 million in 2022, then slumped by 75.78% to $5.5 million in 2023, then soared by 30.65% to $7.1 million in 2024, then retreated by 3.29% to $6.9 million in 2025, then retreated by 2.9% to $6.7 million in 2026.
- Per Business Quant, the three latest DBVT Total Non-Current Liabilities figures stand at $6.7 million (Q1 2026), $6.9 million (Q4 2025), and $8.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 6.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 7.78 Mn |
| Mar 31, 2025 | 7.31 Mn |
| Dec 31, 2024 | 7.14 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Mar 31, 2024 | 7.76 Mn |
| Dec 31, 2023 | 5.46 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 19.91 Mn |
| Mar 31, 2023 | 21.06 Mn |
| Dec 31, 2022 | 22.54 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Jun 30, 2022 | 10.13 Mn |
| Mar 31, 2022 | 9.49 Mn |
| Dec 31, 2021 | 16.05 Mn |
| Sep 30, 2021 | 20.22 Mn |
| Jun 30, 2021 | 18.87 Mn |
| Mar 31, 2021 | 13.40 Mn |
| Dec 31, 2020 | 14.04 Mn |
| Jun 30, 2020 | 21.83 Mn |
| Dec 31, 2019 | 24.18 Mn |
| Sep 30, 2019 | 26.79 Mn |
| Jun 30, 2019 | 27.57 Mn |
| Dec 31, 2018 | 7.90 Mn |
| Jun 30, 2018 | 12.44 Mn |
| Dec 31, 2017 | 14.08 Mn |
| Jun 30, 2017 | 15.09 Mn |
| Dec 31, 2016 | 16.90 Mn |
| Jun 30, 2016 | 14.74 Mn |
| Dec 31, 2015 | 5.68 Mn |
| Jun 30, 2015 | 6.03 Mn |
| Dec 31, 2014 | 5.52 Mn |